Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 951 - 1,000 out of 6,635

Document Document Title
WO2003094842A3
Disclosed are conjugates comprising a central nervous system-active drug linked through an amide bond to a glucuronic acid or glucosamine moiety, and uses thereof, e.g., for treating or ameliorating central nervous system diseases or dis...  
WO/2004/024744A2
Methods and materials are provided for E. coli host cells containing an expression system for producing NDP 6-deoxy-sugar, which may also comprise an expression system for expressing 6-deoxyglycosyl transferase and/or an expression syste...  
WO2004011477A3
Novel 6,11-4-carbon bridged ketolides, pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also de...  
WO/2004/022572A1
A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceut...  
WO/2004/019958A1
A compound represented by the general formula (I) (wherein R1 is H, optionally substituted C1-6 alkyl, etc.; either of Q and T is the group of the formula (II) or the formula (III) and the other is optionally substituted C1-6 alkyl or cy...  
WO2003105766A3
The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines ...  
WO2003090679A3
Antibacterial compounds having formula (I) and formula (II), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and metho...  
WO/2004/019879A2
Motilide compounds having the formula (I), wherein R1, R2, R3, and R4 are as defined herein, and methods for their preparation and use in the treatment of diseases or conditions characterized by impaired gastric motility.  
WO2002068442A8
A compound of formula wherein X<-> is an anion; n is 1, 2, 3 or 4; R1 is C1-C12alkyl, C3-C8cycloalkyl; or C2-C12alkenyl; R2 is hydrogen, unsubstituted or substituted C1-C12alkyl or C2-C12alkenyl; R3 is hydrogen, unsubstituted or substitu...  
WO2003022844A3
The present invention provides compounds of formula (I): as described generally and in classes and subclasses herein. The present invention additionally provides pharmaceutical compositions comprising compounds of formula (I) and provide...  
WO/2004/018491A1
A pyrazole derivative represented by the general formula (I) [wherein R1 is H, optionally substituted C1-6 alkyl, etc.; either of Q and T is the group of the formula (II) or the formula (III) and the other is optionally substituted C1-6 ...  
WO/2004/016634A1
Novel 11-12 substituted lactone ketolide derivatives and pharmaceutically­acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are...  
WO/2004/016632A2
Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are us...  
WO2004000864A3
There are described 11-C-substituted derivatives of erythromycin and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable ...  
WO2002068438A3
The invention relates to 9a-N[N'-(phenylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolid e A, novel semisynthetic macrolide antibiotics from t...  
WO/2004/016633A1
The hydrobromide salt of morphine-6-β-D-glucuronide (M6G.HBr) is surprisingly stable compared to other M6G salts and M6G base. Use of M6G.HBr as a medicament, in particular as an analgesic, and methods of making M6G.HBr are described.  
WO2003059255A3
A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A. In particular, the process for preparing wate...  
WO/2004/014295A2
Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumul...  
WO/2004/014405A1
The invention relates to the use of Ginkgo biloba extracts and, in particular, Ginkgo biloba extracts comprising between 20 and 30 % flavoneglycosides, between 2.5 and 4.5 % in total of ginkgolides A, B, C and J, between 2 and 4 % biloba...  
WO/2004/014932A1
A pyrazole derivative represented by the general formula (I) (wherein R1 is H, optionally substituted C1-6 alkyl, etc.; either of Q and T is the group of the formula (II) or the formula (III) and the other is optionally substituted C1-6 ...  
WO2003020236A3
The present invention relates to a natural extract from fungus, cyanobactria, plants, lichens or a mixture thereof having an ultra violet absorbency in the range of 220 nm to 425 nm wherein said extract is obtained by contacting said fun...  
WO2002097082A3
The complete DNA sequence of the gene cluster encoding the polypeptides responsible for the biosynthesis of the polyene antibiotic amphotericin of S. nodosus is provided. Engineered alteration of the amphC) gene so as to eliminate produc...  
WO/2004/013153A2
Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmace...  
WO/2004/013342A1
Novel substances of compounds PF1237A, PF1237B and PF1237M exhibiting antifungal activity; a process for producing these novel compounds through culturing of PF1237 producing strain belonging to the genus Fusarium; and an antifungal agen...  
WO/2004/012746A2
The present invention provides methods of treating cancer using inhibitors of inosine monophosphate dehydrogenase (IMPDH). The IMPDH inhibitors are combined with compounds that inhibit cellular processes regulated by GTP or ATP. Also pro...  
WO2003040094A3
The invention features a new solid supports having at least one amino functionality and a linker bound to the solid support through at least a portion of the amino functional groups. The invention also features solid support bound substr...  
WO/2004/011477A2
Novel 6,11-4-carbon bridged ketolides, pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also de...  
WO/2004/011009A1
Novel 6,11-4-carbon bridged erythromycin derivatives and pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are ...  
WO/2004/009608A2
Substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. In addition, this disclosure is directed to a process for the preparation thereof from crude 9-deoxo-9a-aza-9a­methyl-9a-homoerythromycin A via orthorhombic is...  
WO/2004/009059A1
Composition for oral administration of telithromycin comprising : spherical agglomerates of telithromycin ; ethylcellulose ; an acrylic polymer ; anti-agglomeration agentwhere the composition is in the form of microcapsules having a 2 la...  
WO/2004/009061A2
The invention relates to the isolation and preparation of an active fraction from plant Cuminum cyminum, its further purification and standardization as chemically defined entity (ies) with their intended use as drug bioavailability enha...  
WO/2004/007518A1
The present invention relates to new erythromycin A 9-O-pseudosaccharinyloxime derivatives represented by Formula 1, and to a new method for preparing 6-O-methylerythromycin A (clarithromycin) as macrolide compound, represented by Formul...  
WO2003068791A3
Compounds having activity against methicillin-resistant staphylococcus aureus (MRSA), the compounds having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the ...  
WO2003064439A3
The invention relates to the use of sialic carbohydrates of general formula (I), containing at least one carbohydrate unit of general formula (II) for the immune modulation, immune suppression and in the prevention and treatment of infec...  
WO/2004/007517A1
The invention relates to novel thiophenylglycoside derivatives of formula (I), where the groups have the given meanings, the physiologically-acceptable salts and methods for production thereof. The compounds are suitable as anti-diabetic...  
WO/2004/005311A1
The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof. Processes for the isolating of this bafilomycin metabolite from a novel Micromonospora species, pharmaceutical compositions containing this m...  
WO/2004/005310A2
The present invention relates (a) to new compounds represented by Formula (I): wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents...  
WO/2004/004646A2
The present invention provides compounds of formula (I) having potent antibiotic activity, including activity towards Gram-positive bacteria and mycobacteria.  
WO/2004/005228A1
The invention provides olive-derived hydroxytyrosol. According to one aspect of the invention, vegetation water is collected from olives. Acid is added to stabilize the vegetation water and prevent fermentation. The mixture is incubated ...  
WO/2004/005309A2
The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a...  
WO/2004/005259A1
A drug delivery system of a substituted hydroxypyridine compound which comprises: i) orally administering the substituted hydroxypyridine compound, ii) converting the substituted hydroxypyridine compound into a conjugate during the absor...  
WO/2004/002470A1
The present invention provides novel antidipsotropic compounds. The invention further provides methods of inhibiting ALDH-2 using the compounds described herein. Methods for modulating alcohol consumption, alcohol dependence and/or alcoh...  
WO/2004/002998A1
In accordance with the present invention there is provided a method for the separation of a triglycoalkaloid in which the triglycoside portion comprises &agr -L-rhamnopyranosyl-(1→2gal)-O-β-D-glucopyranosyl-(1→3ga l)-ß-D-galactopyr...  
WO/2004/002496A1
The invention concerns the use of a hesperidin compound or one of its derivatives for making a composition for stimulating bone formation and/or for inhibiting calcium resorption from bone in humans or animals.  
WO/2004/000864A2
There are described 11-C-substituted derivatives of erythromycin and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable ...  
WO/2004/000865A1
A pharmaceutical composition for oral administration, comprising azithromycin in the form of a monohydrate as a pharmaceutically active ingredient, a sweetener, a flavourant, a buffer, optionally a filler, and optionally a thickener.  
WO2003094911B1
A method for treating and/or preventing hepatic disease conditions in mammals including human beings, said method comprising the steps of administering to the mammal an effective amount of 10-O-p-hydroxybenzoylaucubin compound of Formula...  
WO/2004/000866A1
There are described 11-C-substituted derivatives of clarithromycin and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptabl...  
WO/2003/105766A2
The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines ...  
WO/2003/106413A2
A process for preparing N-(substituted)-C­- (substituted methyl)-oxazolidinones, C-(substituted methyl)-oxazolidinones, and N-(substituted)-C­- (substituted ethyl)-oxazolidinones, preferably chiral, from optically active C-(protected o...  

Matches 951 - 1,000 out of 6,635